Discover more
than you think

Developing innovative cancer treatments tackling GPCR mediated-immunosuppression

 

Learn more

Immuno-oncology
pipeline

  Discovery
Candidate
Preclinical
Clinical
Partner
A2aR/A2bR antagonist +
Preclinical
EP4 receptor antagonist ( DT-9081 ) +
Preclinical
Anti-CCR8 antibody +
Discovery
Undisclosed GPCR targets +
Discovery

Our unique positioning

We build a high value pipeline focused on GPCRs to rearm immune system against tumors.

Immuno-oncology
programs

We are advancing multiple first-in-class and best-in class programs to tackle GPCR-mediated immunosuppression in immune-oncology.

Learn more

  • Takeda is one of Domain Therapeutics’s partners
  • Lundbeck is one of Domain Therapeutics’s partners
  • Takeda is one of Domain Therapeutics’s partners
  • Lundbeck is one of Domain Therapeutics’s partners
  • Takeda is one of Domain Therapeutics’s partners
  • Lundbeck is one of Domain Therapeutics’s partners